The antiserum was produced against synthesized peptide derived from human GluR2 around the phosphorylation site of Ser880. AA range:834-883

Phospho-GluR-2 (S880) Polyclonal Antibody detects endogenous levels of GluR-2 protein only when phosphorylated at S880.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):IEsVK

GRIA2 GLUR2

Glutamate receptor 2

GRIA2 ;
GLUR2 ;
Glutamate receptor 2 ;
GluR-2 ;
AMPA-selective glutamate receptor 2 ;
GluR-B ;
GluR-K2 ;
Glutamate receptor ionotropic ;
AMPA 2 ;
GluA2

Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to a family of glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) , and function as ligand-activated cation channels. These channels are assembled from 4 related subunits , GRIA1-4. The subunit encoded by this gene (GRIA2) is subject to RNA editing (CAG->CGG; Q->R) within the second transmembrane domain , which is thought to render the channel impermeable to Ca (2+) . Human and animal studies suggest that pre-mRNA editing is essential for brain function , and defective GRIA2 RNA editing at the Q/R site may be relevant to amyotrophic lateral sclerosis (ALS) etiology. Alternative splicing , resulting in transcript variants enco

Function:Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change , leading to the opening of the cation channel , and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state , characterized by the presence of bound agonist. ,miscellaneous:The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds AMPA (quisqualate) > glutamate > kainate. ,PTM:Palmitoylated. Depalmitoylated upon glutamate stimulation. Cys-610 palmitoylation leads to Golgi retention and decreased cell surface expression. In contrast , Cys-836 palmitoylation does not affect cell surface expression but regulates stimulation-dependent endocytosis. ,RNA editing:Partially edited. Fully edited in the brain. Heteromerically expressed edited GLUR2 (R) receptor complexes are impermeable to calcium , whereas the unedited (Q) forms are highly permeable to divalent ions. ,similarity:Belongs to the glutamate-gated ion channel (TC 1.A.10) family. ,subunit:Homotetramer or heterotetramer of pore-forming glutamate receptor subunits. Tetramers may be formed by the dimerization of dimers. May interact with MPP4. Forms a ternary complex with GRIP1 and CSPG4. Interacts with PRKCABP , GRIP1 and GRIP2. ,

Cell membrane ; Multi-pass membrane protein . Endoplasmic reticulum membrane ; Multi-pass membrane protein . Cell junction , synapse , postsynaptic cell membrane ; Multi-pass membrane protein . Cell junction , synapse , postsynaptic density membrane ; Multi-pass membrane protein . Interaction with CACNG2 , CNIH2 and CNIH3 promotes cell surface expression (By similarity) . Displays a somatodendritic localization and is excluded from axons in neurons (By similarity) . .

>>cAMP signaling pathway ;
>>Neuroactive ligand-receptor interaction ;
>>Circadian entrainment ;
>>Long-term potentiation ;
>>Retrograde endocannabinoid signaling ;
>>Glutamatergic synapse ;
>>Dopaminergic synapse ;
>>Long-term depression ;
>>Amyotrophic lateral sclerosis ;
>>Huntington disease ;
>>Spinocerebellar ataxia ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Cocaine addiction ;
>>Amphetamine addiction ;
>>Nicotine addiction